IP Library Granted Patent US 8,062,677
Granted Patent B2
US 8,062,677 · App. 12/340,257 · Granted Nov 22, 2011

Methods and compositions for the sustained release of chromium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,062,677
App. No.
12/340,257
Granted
Nov 22, 2011
Kind
B2
Abstract

Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Claims (6)

1. A composition for administering chromium over a period of time, the composition comprising a synergistic ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex,

wherein the hydrophilic chromium complex is selected from the group consisting of chromium acetate, chromium chloride, chromium histidinate and chromium nicotinate, the lipophilic chromium complex is chromium picolinate, and the synergistic ratio is between about 1:2 and 2:1.

2. A composition for administering chromium over a period of time, the composition consisting essentially of chromium histidinate and chromium picolinate.

3. The composition of claim 1 , wherein said hydrophilic chromium complex is chromium histidinate.

4. The composition of claim 1 , further comprising a nutritionally acceptable carrier.

5. A composition for providing bioavailable chromium, the composition comprising chromium histidinate and chromium picolinate, wherein the ratio of chromium histidinate to chromium picolinate is between about 1:2 and 2:1.

Assignments (5)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
CHANGE OF NAME Recorded Jun 14, 2012
From: N21 ACQUISITION HOLDING, LLC
To: JDS THERAPEUTICS, LLC
Reel/Frame 028603/0993 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2012
From: NUTRITION 21, INC.
To: N21 ACQUISITION HOLDING, LLC
Reel/Frame 027545/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2009
From: KOMOROWSKI, JAMES R.
To: NUTRITION 21, INC.
Reel/Frame 022340/0359 →